Announcements Trials
Browse Landscape

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Genitourinary 4Breast 3Other hematologic neoplasm 2Gynecologic 2Endocrine 2Sarcoma 1NET 1Lymphoid 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 14Specimen Handling 8Magnetic Resonance Spectroscopy 8Everolimus 8cabozantinib 6pembrolizumab 5Nivolumab 4olaparib 3lenvatinib 3X-Rays 3Lutetium-177 3Cyclophosphamide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3lanreotide 2gallium Ga 68 dotatate 2fludarabine phosphate 2fludarabine 2avelumab 2amino-acid, glucose, and electrolyte solution 2Sunitinib 2Radiotherapy 2Phantoms, Imaging 2Octreotide 2Ipilimumab 2Fluorodeoxyglucose F18 2Etoposide 2Cisplatin 23-aminopyridine-2-carboxaldehyde thiosemicarbazone 2telotristat ethyl 1surufatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Positron-Emission Tomography × NET × 90 days × Clear all
NCT06448208 2026-03-09

Defining Response Criteria for PET Scans for People With Neuroendocrine Tumors

Memorial Sloan Kettering Cancer Center

Active not recruiting
11 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡